BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.00), $0.28 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $154.2 million versus the consensus estimate of $146.16 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.